Owlet Performance degli utili passati
Criteri Il passato verificati 0/6
Owlet ha registrato una crescita degli utili a un tasso medio annuo di 13.3%, mentre il settore Medical Equipment ha registrato utili in crescita a un tasso medio annuo di 15.3%. I ricavi sono stati in crescita a un tasso medio annuo di 4.7%.
Informazioni chiave
13.27%
Tasso di crescita degli utili
38.81%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.90% |
| Tasso di crescita dei ricavi | 4.66% |
| Rendimento del capitale proprio | -135.99% |
| Margine netto | -44.60% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • Jun 26
OWLT: Guidance Reset And Adoption Initiatives Will Support Future Execution
Analysts have trimmed their fair value estimate for Owlet from $17.00 to $13.00, reflecting updated assumptions on growth, profitability, and P/E, while still pointing to potential upside supported by views that the recent guidance reset and improving hardware and subscription features could attract more customers over time. What's in the News for Owlet Owlet launched Dream Sight and Dream Duo 3 across Australia and New Zealand, bringing its full lineup of baby monitoring products, including Dream Sock, to those markets for the first time.
Aggiornamento della narrazione • Jun 04
OWLT: Softer Q1 Guide Seen Preceding Stronger 2026 Second Half
Narrative Update The analyst price target for Owlet has been reduced from $20 to $15, with analysts pointing to softer Q1 guidance, while also noting 2026 expectations that suggest a more robust back half of that year. What's in the News Owlet launched Dream Sight and Dream Duo 3 across Australia and New Zealand, expanding its full baby monitoring product lineup in those markets, including Dream Sock, Dream Sight, and Dream Duo 3.Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking AlphaAggiornamento della narrazione • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Aggiornamento della narrazione • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.Aggiornamento della narrazione • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.Aggiornamento della narrazione • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.Aggiornamento della narrazione • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.Aggiornamento della narrazione • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.
Aggiornamento della narrazione • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.Articolo di analisi • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...Aggiornamento della narrazione • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.Aggiornamento della narrazione • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.Aggiornamento della narrazione • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.Articolo di analisi • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...Aggiornamento della narrazione • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.Aggiornamento della narrazione • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.Articolo di analisi • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...Aggiornamento della narrazione • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.Articolo di analisi • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
Nuova narrazione • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.Articolo di analisi • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Owlet guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 107 | -48 | 50 | 15 |
| 31 Dec 25 | 106 | -42 | 48 | 14 |
| 30 Sep 25 | 100 | -42 | 50 | 13 |
| 30 Jun 25 | 90 | -52 | 50 | 12 |
| 31 Mar 25 | 84 | -17 | 49 | 10 |
| 31 Dec 24 | 78 | -17 | 48 | 10 |
| 30 Sep 24 | 79 | -11 | 43 | 10 |
| 30 Jun 24 | 66 | -11 | 40 | 9 |
| 31 Mar 24 | 58 | -19 | 39 | 10 |
| 31 Dec 23 | 54 | -33 | 41 | 10 |
| 30 Sep 23 | 45 | -49 | 50 | 13 |
| 30 Jun 23 | 53 | -61 | 60 | 17 |
| 31 Mar 23 | 58 | -63 | 70 | 22 |
| 31 Dec 22 | 69 | -79 | 80 | 28 |
| 30 Sep 22 | 55 | -84 | 75 | 31 |
| 30 Jun 22 | 69 | -99 | 78 | 30 |
| 31 Mar 22 | 75 | -93 | 74 | 27 |
| 31 Dec 21 | 76 | -72 | 64 | 21 |
| 30 Sep 21 | 99 | -53 | 60 | 17 |
| 30 Jun 21 | 89 | -20 | 46 | 14 |
| 31 Mar 21 | 82 | -16 | 38 | 11 |
| 31 Dec 20 | 75 | -11 | 32 | 10 |
| 31 Dec 19 | 50 | -18 | 29 | 11 |
Guadagni di qualità: OWLT al momento non è redditizia.
Margine di profitto in crescita: OWLT al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: OWLT non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 13.3% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di OWLT nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: OWLT non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Medical Equipment ( 14.8% ).
Rendimento del capitale proprio
ROE elevato: OWLT ha un Return on Equity negativo ( -135.99% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/06 04:16 |
| Prezzo dell'azione a fine giornata | 2026/07/06 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Owlet, Inc. è coperta da 8 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |